Source:
Healio Interview
Leal T. Small Cell Lung Cancer: How Will We Sequence Immunotherapy and Novel Agents. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
Socinski MA. Squamous Cell Lung Cancer, Mesothelioma, and Thymoma: Management Updates. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
Disclosures:
Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.